Payment overview · 2025
General Payments
$3,572.72
191 reported records · 30 companies
Healthcare provider profile · identity verified
Neeraj Manchanda, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AUSTIN, TX · NPI 1790711976
Verified facts
What the public records show
CMS Open Payments records show Neeraj Manchanda, M.D. received $3,572.72 in general payments during 2025 across 191 reported records.
Lilly USA, LLC accounted for 9.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lumryz, Nurtec Odt, Rexulti.
Avadel CNS Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMRYZ as an associated drug or biological on 11767 records involving 3739 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumryz by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $335.38 | 9.4% | 16 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$318.80 | 8.9% | 16 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $300.46 | 8.4% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $274.75 | 7.7% | 27 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $231.15 | 6.5% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $222.35 | 6.2% | 9 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $221.39 | 6.2% | 11 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $188.23 | 5.3% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $188.08 | 5.3% | 17 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $151.19 | 4.2% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $149.86 | 4.2% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.14 | 3.5% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $106.06 | 3.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.01 | 2.8% | 4 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $91.60 | 2.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $89.90 | 2.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $86.26 | 2.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.21 | 2.4% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $58.29 | 1.6% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $49.74 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.58 | 0.8% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $27.37 | 0.8% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $19.64 | 0.6% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $19.53 | 0.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.36 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.33 | 0.5% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $18.32 | 0.5% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.68 | 0.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.67 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.39 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,502.73 | 190 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $320.97 | 13 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $272.22 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $242.85 | 21 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $222.35 | 9 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $221.39 | 11 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $188.23 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $188.08 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.54 | 15 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $156.07 | 10 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $151.19 | 9 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $144.46 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $142.23 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.23 | 19 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $103.63 | 11 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $99.01 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $93.89 | 4 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $91.60 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $89.90 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $86.69 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $85.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.65 | 4 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.90 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $29.50 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $27.37 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LUMRYZ lumryz |
2025 | Lumryz | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Avadel CNS Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | LUMRYZ open payments reported associated product |
CMS Open Payments — General Payments 11767 supporting records · 3739 recipient NPIs · example record 1208530440 |
Lumryz · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 974 | 329 |
| Memantine Hcl | Memantine Hcl | 665 | 204 |
| Gabapentin | Gabapentin | 483 | 149 |
| Lamotrigine | Lamotrigine | 364 | 94 |
| Sertraline Hcl | Sertraline Hcl | 339 | 90 |
| Divalproex Sodium Er | Divalproex Sodium | 247 | 67 |
| Propranolol Hcl | Propranolol Hcl | 185 | 58 |
| Levetiracetam | Levetiracetam | 179 | 47 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 177 | 44 |
| Pregabalin | Pregabalin | 158 | 44 |
| Trazodone Hcl | Trazodone Hcl | 114 | 32 |
| Topiramate | Topiramate | 95 | 26 |
| Buspirone Hcl | Buspirone Hcl | 89 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 28 |
| Primidone | Primidone | 70 | 18 |
| Aimovig Autoinjector | Erenumab-Aooe | 69 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Lacosamide | Lacosamide | 67 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 66 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 53 | 21 |
| Xcopri | Cenobamate | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 20 |
| Emgality Pen | Galcanezumab-Gnlm | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 16 |
| Zonisamide | Zonisamide | 41 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 39 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 32 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ingrezza | Valbenazine Tosylate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Fycompa | Perampanel | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nourianz | Istradefylline | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | 11 |
| Lumryz | Sodium Oxybate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,572.72 · 191 records | Lilly USA, LLC | AJOVY, AMYVID, AUSTEDO XR, Azstarys, BRIUMVI, CREXONT, EPIDIOLEX, HORIZANT, INFINITY, INSPIRE, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, MOUNJARO, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REXULTI, SYMPAZAN, Symbravo, TYSABRI, UBRELVY, VRAYLAR, VUMERITY, VYEPTI, VYVGART HYTRULO, WAKIX, XYWAV, ZAVZPRET, ZEPBOUND, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lumryz play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Avadel CNS Pharmaceuticals, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error